Compounded semaglutide is not FDA-approved. FDA declared the semaglutide injection shortage resolved on February 21, 2025. Its enforcement grace period ended April 22, 2025 for 503A pharmacies, and May 22, 2025 for 503B outsourcing facilities, for products that are essentially copies of the approved drug. (FDA)

Pharmacies can still compound semaglutide for an individual patient when a prescriber documents a medical need the approved drug can't meet and the product is not essentially a copy. That is why some telehealth sellers still list it. FDA says compounded drugs are not reviewed for safety, effectiveness, or quality before marketing (FDA).

Questions to ask before you buy

  • Which pharmacy compounds it, and is it a 503A pharmacy or a 503B outsourcing facility? See our sourcing transparency guide.
  • Is it semaglutide base, or a salt form such as semaglutide sodium? FDA has warned about salt forms.
  • What is the dose cap per shipment, and does the price change as your dose goes up?
  • Is a membership fee charged on top of the medication price?
  • What is the refund policy once medication ships?

Compare clinics that list semaglutide in the provider directory, or read compounded vs. brand semaglutide and our safety checklist.